Breast Cancer Now media statements
We respond to NHS England breast cancer waiting times: September 2020 and Q2 20/21
NHS England cancer waiting times data from September 2020 show:
Response to the Spending Review 2020
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:
We respond to the Scotland Cancer Recovery Plan
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:
We respond to RxPONDER trial results that suggest postmenopausal women with early-stage breast cancer/low recurrence score could skip adjuvant chemo
Dr Kotryna Temcinaite, Senior Research Communications Manager at Breast Cancer Now, said:
We respond to NHS England breast cancer waiting times for November 2020
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:
We Respond to Breast Cancer Screening Performance Data for England 2019/20
New figures from NHS Digital, taken from the performance data on the breast screening programme for England between April 2019 and March 202...
We respond to breast cancer becoming the most common cancer globally
Dr Simon Vincent, Director of Research, Support and Influencing at Breast Cancer Now, said:
We respond to draft NICE decision not to recommend abemaciclib with fulvestrant for routine use on the NHS
The National Institute for Health and Care Excellence (NICE) has today announced its decision to provisionally not recommend breast cancer t...
We welcome NICE approval of ribociclib with fulvestrant for use on the NHS
The National Institute for Health and Care Excellence (NICE) has today announced its decision to approve ribociclib with fulvestrant for rou...